Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up - Concepedia

Concepedia

Publication | Closed Access

Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up

501

Citations

31

References

2002

Year

Stein Sundstrøm, Roy M. Bremnes, Stein Kaasa, Ulf Aasebø, Reidulv Hatlevoll, Ragnar Dahle, Nils P. Boye, Mari Wang, T Vigander, Jan Vilsvik,

Journal of Clinical Oncology

Abstract

EP is superior to CEV in LD-SCLC patients. In ED-SCLC patients, the benefits of EP and CEV chemotherapy seem equivalent, with similar survival time and quality of life.

References

	Year	Citations

Page 1